Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Fragment-based Sequential Translation for Molecular Optimization

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Fragment and Geometry Aware Tokenization of Molecules for Structure-Based Drug Design Using Language Models

A Tree-Transformer based VAE with fragment tokenization for large chemical models

Fragment‐based Deep Molecular Generation using Hierarchical Chemical Graph Representation and Multi‐Resolution Graph Variational Autoencoder

Molecule Generation with Fragment Retrieval Augmentation

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

Unlocking comprehensive molecular design across all scenarios with large language model and unordered chemical language

Scalable Fragment-Based 3D Molecular Design with Reinforcement Learning

MolMiner: Transformer architecture for fragment-based autoregressive generation of molecular stories

FraHMT: A Fragment-Oriented Heterogeneous Graph Molecular Generation Model for Target Proteins

Black Box Recursive Translations for Molecular Optimization

Leveraging Tree-Transformer VAE with fragment tokenization for high-performance large chemical generative model

Fragment-Masked Molecular Optimization

Gotta be SAFE: A New Framework for Molecular Design

FAME: Fragment-based Conditional Molecular Generation for Phenotypic Drug Discovery

SAFE setup for generative molecular design

Conditional Latent Space Molecular Scaffold Optimization for Accelerated Molecular Design

FragLlama: Next-fragment Prediction for Molecular Design

Generative Model for Small Molecules with Latent Space RL Fine-Tuning to Protein Targets